IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...
biote Corp. returned to profitability in Q3 2023 and is expected to continue to be profitable in the future. The company's growth is driven by the sale of hormone replacement therapy products and its ...
This article first appeared on GuruFocus. Biote Corp (NASDAQ:BTMD) is set to release its Q3 2025 earnings on Nov 5, 2025. The consensus estimate for Q3 2025 revenue is $47.76 million, and the earnings ...
Biote Corp. ((BTMD)) has held its Q3 earnings call. Read on for the main highlights of the call. Biote Corp.’s latest earnings call revealed a mixed sentiment, with challenges and opportunities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results